Consenso de la Asociación Colombiana de Neurología sobre el uso de apomorfina en la enfermedad de Parkinson
Vol. 34 Núm. 1 (2018), Consenso, guías y recomendaciones
Vol. 34 Núm. 1 (2018)

Consenso de la Asociación Colombiana de Neurología sobre el uso de apomorfina en la enfermedad de Parkinson

Consenso, guías y recomendaciones
https://doi.org/10.22379/24224022176
Publicado 01-01-2018
Claudia Lucía Moreno López
Médico y Neurólogo de la Universidad del Rosario; Especialista en Trastornos del Movimiento, Hospital Clinic de Barcelona; Neuróloga clínica, Unidad de Movimientos Anormales, Fundación Cardioinfantil y Grupo de Cirugía Funcional en Trastornos del Movimiento del Hospital San Ignacio. Docente de Neurología, Universidad del Rosario, pregrado y posgrado de Neurología; coordinadora del Comité de Movimientos Anormales de la Asociación Colombiana de Neurología, Bogotá, Colombia
Oscar Bernal Pacheco
Médico, Universidad Nacional de Colombia y Neurólogo de la Universidad Militar Nueva Granada; Especialista en Trastornos del Movimiento, Universidad de la Florida; Neurólogo clínico, Hospital Militar Central, Fundación Santafé e Instituto Roosevelt. Docente de Neurología, Universidad Militar Nueva Granada; coordinador del Comité de Movimientos Anormales de la Asociación Colombiana de Neurología, Bogotá, Colombia
Gustavo Barrios Vincos
Médico y Neurólogo de la Universidad del Bosque; Especialista en Trastornos del Movimiento, Universidad Federal de Río de Janeiro; Master Propio en trastornos del Movimiento, Universidad de Murcia; Neurólogo clínico, Unidad de Trastornos del Movimiento, Hospital Occidente de Kennedy. Profesor clínico, posgrado de Neurología, Universidad de la Sabana, Bogotá, Colombia
Gabriel Arango Uribe
Médico y Neurólogo de la Universidad Nacional de Colombia; Neurólogo clínico, Clínica de Marly; Grupo de Neurocirugía Funcional, Instituto Latinoamericano de Neurología y Sistema Nervioso (ILANS), Bogotá, Colombia
Catalina Cerquera Cleves
Médica, Universidad Nacional de Colombia; Neuróloga, Pontificia Universidad Javeriana. Especialista en enfermedad de Parkinson y trastornos del movimiento, Hospital Clínic de Barcelona, Universidad de Barcelona. Neuróloga del Hospital Universitario San Ignacio y Clínica del Country. Docente de posgrado en Neurología, Pontificia Universidad Javeriana, Bogotá, Colombia
Jorge Luis Orozco Vélez
Neurólogo clínico, Jefe de Neurología y profesor investigador, Fundación Valle de Lili, Universidad Icesi, Cali, Colombia
Paula Millán
Neuróloga, Universidad de Antioquia; Trastornos del Movimiento, Hospital Clinic de Barcelona, Hospital Germans Trias, Pujol de Baladona; Unidad de Trastornos del Movimiento, Instituto Neurológico de Colombia; profesor clínico, posgrado de Neurología, Universidad CES, Medellín, Colombia
Jesús Alberto Díazgranados Sánchez
Biólogo, Ms Sc Morfología y Médico cirujano de la Universidad del Valle, Neurólogo Clínico, Universidad de Buenos Aires. Director médico, Neurólogos de Occidente, Neurólogo, Centro Médico Imbanaco, Cali, Colombia
Xiomara García
Médico cirujano y Neuróloga de la Universidad Nacional de Colombia; Especialista en desórdenes del movimiento de Cleveland Clinic Foundation; Neuróloga clínica, Grupo de Neurocirugía Funcional, Instituto Latinoamericano de Neurología y Sistema Nervioso (ILANS), Fundación Hospital San Carlos, Bogotá, Colombia
Mauricio Rueda Acevedo
Neurólogo, Hospital Militar Central; Especialista en Movimientos Anormales, Cleveland Clinic. Especialista en Movimientos Anormales en Clínica SOMA y Neuromedica, Medellín; Especialista en Movimientos Anormales, Hospital Internacional de Colombia, Bucaramanga
Omar Buritica
Neurólogo de la Universidad de Antioquia, especialista en enfermedad de Parkinson y otros Movimientos Anormales, The National Hospital for Neurology and Neurosurgery, Queen Square. Profesor neurología, Universidad de Antioquia, CES, UPB; Miembro del Grupo de Investigación de Neurociencias de la Universidad de Antioquia, SIU; Miembro Grupo de Trastornos de Movimientos del Instituto Neurológico de Colombia; Miembro Grupo de Neurocirugía, Funcional FHUSVP; Neurólogo, Hospital Pablo Tobón Uribe, Medellín, Antioquia
Juan Camilo Rodríguez-Carrillo
Médico, Universidad Nacional de Colombia; Neurólogo, Hospital de la Princesa, Madrid, España; Especialista en Trastornos del Movimiento, Universidad de California, San Diego EE. UU.; Master Propio en Trastornos del Movimiento, Universidad de Murcia, España; Coordinador Consulta de Movimientos Anormales, Clínica la Misericordia Internacional, Barranquilla, Colombia
PDF
XML

Palabras clave

enfermedad de Parkinson
apomorfina
bombas de infusión
consenso (DeCS)

Resumen

La apomorfina es un agonista dopa que se viene usando desde hace más 25 años en el tratamiento de la enfermedad de Parkinson avanzada con complicaciones motoras complejas, por lo cual sigue siendo de gran importancia en el tratamiento de esta etapa de la enfermedad.

En el siguiente escrito, realizado por el Comité de Movimientos Anormales de la Asociación Colombiana de Neurología, se hace una revisión respecto a la medicación, su eficacia y el papel en el manejo de la enfermedad de Parkinson, así como una comparación entre las diferentes terapias avanzadas disponibles hoy en día. De la misma manera el Comité hace recomendaciones sobre las indicaciones, elección de candidatos y protocolos para el inicio de las diferentes formas de administración (intermitente e infusión continua) para optimizar el uso de esta terapia y facilitar la adherencia al tratamiento.

Por otra parte, se revisan los efectos adversos relacionados con la terapia y se hacen recomendaciones sobre el manejo de las mismas, el seguimiento que se debe hacer a los pacientes que reciban apomorfina y las claves en el tratamiento a largo plazo.

https://doi.org/10.22379/24224022176
PDF
XML

Citas

Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I. Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology. JRSM. 2004;97(2):84-5.

Taba P, Lees A, Stern G. Erich Harnack (1852-1915) and a short history of apomorphine. EurmNeurol. 2013;69(6):321-24. https://doi.org/10.1159/000346762.

Morales-Rosado JA, Cousin IMA, Ebbert JO, Klee EW A critical review of repurposing apomorphine for smoking cessation, Assay. Drug Dev Technol. 2015;13(10):612-622. https://doi.org/10.1089/adt.2015.680.

Djamshidian A, Poewe W Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. Parkinsonism Relat Disord. 2016;33(Suppl 1):S9-S12. https://doi.org/10.1016/j.parkreldis.2016.12.004.

Lees A. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3-4):121-28.

Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord. 2016;33(Suppl 1):S13-S21. https://doi.org/10.1016/j.parkreldis.2016.12.003.

Menonn R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2007;8(12):1941-50. https://doi.org/10.1517/14656566.8.12.1941.

Mohee A, Bretsztajn L, Eardley I. The evaluation of apomorphine for the treatment of erectile dysfunction. Expert Opin Drug Metab Toxicol. 2012;8(11):1447-53. https://doi.org/10.1517/17425255.2012.727797.

Heaton JP. Key issues from the clinical trials of apomorphine SL. World J Urol 2001;19(1):25-31.

Cotzias G, Papavasiliou P, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med. 1970;282(1):31-33. https://doi.org/10.1056/NEJM197001012820107.

Cotzias G, Papavasiliou P, Tolosa E, Mendez J, Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976;294(11):567-72. https://doi.org/10.1056/NEJM197603112941101.

Papavasiliou P, Cotzias G, Rosal V, Miller S. Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa). Arch Neurol. 1978:35(12):787-91.

Ernst A. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia. 1965;7(6):391-99.

Corsini G, Del Zompo M, Gessa G, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1979;1(8123):954-56.

Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctutations. Lancet. 1987;1(8537):871.

Obeso JA, Grandas F, Vaamonde J, Rosario Luguin M, Martínez-Lage JM. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet. 1987;1(8546):1376-77.

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791-804. https://doi.org/10.1124/jpet.102.039867.

Dankova J, Bedard P, Langelier P, Poirier LJ. Dopaminergic agents and circling behaviour. Gen Pharmacol. 1978;9(5):295-302. https://doi.org/10.1016/0306-3623(78)90064-2.

Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)- adrenoceptor. J Pharmacol Exp Ther. 2002;303(2):805-14. https://doi.org/10.1124/jpet.102.039875.

Uchiyama T, Sakakibara R, Yoshiyama M, et al. Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience. 2009;162(4):1333-38. https://doi.org/10.1016/j.neuroscience.2009.06.001.

Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord. 2015;30(4):510-16. https://doi.org/10.1002/mds.26067.

Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009;24(1):129-33. https://doi.org/10.1002/mds.22385.

Borgemeester R, Lees A, Van Laar T. Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat Disord. 2016;27:35-40. https://doi.org/10.1016/j.parkreldis.2016.04.023.

Przedborski S, Levivier M, Raftopoulos C, Naini A, Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord. 1995;10(1):28-36. https://doi.org/10.1002/mds.870100107.

Gancher S, Nutt J, Woodward W. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord.1995;10(1):37-43. https://doi.org/10.1002/mds.870100108.

Gancher S, Woodward W, Boucher B, Nutt J. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26:232-38. https://doi.org/10.1002/ana.410260209.

LeWitt P. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl4):S8-S11.

Dewey R Jr., Hutton J, LeWitt P, Factor S. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385-92.

Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol. 1997;20(2):165-67.

Van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg. 1993;95(3):231-5.

Ostergaard L1, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, Boisen E, Jensen NB, Ingwersen SH, Schmiegelow M. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;58(6):681-7.

Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH. APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):93-100. https://doi.org/10.1016/j.parkreldis.2006.06.012.

Pahwa R, Koller WC, Trosch RM, Sherry JH, APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258(1-2):137-43. https://doi.org/10.1016/j.jns.2007.03.013.

Stacy M, Silver D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(2):85-92. https://doi.org/10.1016/j.parkreldis.2007.07.016.

Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. Mov Disord Clin Pract. 2017;4(1):78-83. https://doi.org/10.1002/mdc3.12350.

Tyne H, Parsons J, Sinnott A, Fox S, Fletcher N, Steiger M. A 10 year retrospective audit of longterm apomorphine use in Parkinson's disease. J Neurol. 2004;251(11):1370-74. https://doi.org/10.1007/s00415-004-0547-4.

Frankel J, Lees A, Kempster P, Stern G. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96-101.

Hughes A, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees A, Stern G. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993;8(2):165-170. https://doi.org/10.1002/mds.870080208.

Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709-16.

Chaudhuri K, Critchley P, Abbott R, Pye I, Millac P. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet. 1988;2(8622):1260.

Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E, Ruggieri S. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol. 1993;60:653-55.

Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Longterm follow-up in 18 patients. Adv Neurol. 1993;60:656-59.

Kreczy-Kleedorfer B, Wagner M, Bosch S, Poewe W. Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease. Nervenarzt. 1993;64(4):221-25.

Colzi A, Turner K, Lees A. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(5):573-76.

Wenning G, Bosch S, Luginger E, Wagner M, Poewe W. Effects of longterm, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol. 1999;80:545-48.

Stocchi F, Vacca L, De Pandis M, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci. 2001;22(1):93-94.

Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, Znojil V. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002;17(1):188-191.

Di Rosa A, Epifanio A, Antonini A, Stocchi F, et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci. 2003;24(3):174-75. https://doi.org/10.1007/s10072-003-0116-0.

Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr. 2004;Suppl 9:291-296. https://doi.org/10.1016/j.archger.2004.04.039.

Katzenschlager R, Hughes A, Evans A, Manson A, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees A. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151-57. https://doi.org/10.1002/mds.20276.

De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, Antonini A. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry. 2006;77(4):450-53. https://doi.org/10.1136/jnnp.2005.078659.

García Ruiz PJ1, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130-36. https://doi.org/10.1002/mds.22063.

Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G. A 5- year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apo-morphine infusion or deep brain stimulation. J Neurol. 2011;258(4):579-85. https://doi.org/10.1007/s00415-010-5793-z.

Drapier S, Gillioz AS, Leray E, Peron J, Rouaud T, Marchand A, Verin M. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Park Relat Disord. 2012;18(1):40-44. https://doi.org/10.1016/j.parkreldis.2011.08.010.

Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidencebased review. J Neurol. 2013;260(11):2701-14. https://doi.org/10.1007/s00415-012-6798-6.

Alegret M, Valldeoriola F, Martí M, Pilleri M, Junqué C, Rumià J, Tolosa E. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord. 2004;19(12):1463-69. https://doi.org/10.1002/mds.20237.

Schuepbac WM, Rau J, Knudsen K, Volkmann J, Krack P, Tim-mermann L, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-22. https://doi.org/10.1056/NEJMoa1205158.

Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson's disease. Handb Clin Neurol. 2013;116:107-28. https://doi.org/10.1016/B978-0-444-53497-2.00010-3.

Elia AE, Dollenz C, Soliveri P, Albanese A, et al. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol. 2012; 19(1):76-83. https://doi.org/10.1111/j.1468-1331.2011.03437.x.

Gunzler, S. Apomorphine in the treatment of Parkinson disease and other movement disorders. Expert Opin Pharmacother.2009;10(6):1027-38. https://doi.org/10.1517/14656560902828344.

Stacy, M. Apomorphine: North Americ an clinical experience. Neurology. 2004;62(6 Suppl 4):S18-S21.

Trenkwalder C, et al., Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease e Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):23-1030. https://doi.org/10.1016/j.parkreldis.2015.06.012.

Van Laar T, Van Hilten B, Neef C, Rutgers A, Pavel S, Burijn J. The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: a histologic study. Mov Disord. 1998;13(1):52-55. https://doi.org/10.1002/mds.870130113.

Loewe R, Püspõk-Schwarz M, Petzelbauer P. Apomorphine hyperpigmentation. Hautarzt. 2003;54(1):58-63. https://doi.org/10.1007/s00105-002-0401-5.

Poltawski L, Edwards H, Todd A, Watson T, Lees A, James CA. Ultrasound treatment of cutaneous side-effects of infused apo-morphine: a randomized controlled pilot study. Mov. Disord. 2009;24(1):115-18. https://doi.org/10.1002/mds.22316.

Aarsland D, Larsen J, Lim N, Janvin C, Karlsen K, Tandberg E, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492-96.

Kempster P, Iansek R, Larmour I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med. 1991;21(3):314-318.

Stibe C, Lees A, Kempster P, Stern G. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1(8582):403-406.

Olanow C, Watts R, Koller W. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S1-S88.

O'Sullivan S, Evans A, Lees A. Dopamine dysregulation syndrome: an overview of it epidemiology, mechanisms and management. CNS Drugs. 2009;23(2):157-70. https://doi.org/10.2165/00023210-200923020-00005.

http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Commit-tee/WC500162559.pdf.

Homann C, Suppan K, Homann B, Crevenna R, Ivanic G, Ruzicka E. Driving in Parkinson's disease - a health hazard. J Neurol. 2003;250(12):1439-46. https://doi.org/10.1007/s00415-003-0239-5.

O'Sullivan J, Lees A. Use of apomorphine in Parkinson's disease. Hosp Med. 1999;60(11):816-820.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.

Descargas

Los datos de descargas todavía no están disponibles.